SBC Medical Group Holdings Inc. reported robust financial performance for 2024, achieving an 18% increase in net income despite heightened competition in the aesthetic medical market. The company's full-year revenue reached $205 million, representing a 6% year-over-year growth, driven by strategic expansion and service diversification.
The company operates 251 clinics across Japan and added 43 new locations in 2024, contributing to a 15% increase in annual patient visits. With a customer retention rate exceeding 70% and serving 6 million patients, SBC Medical demonstrated resilience in a competitive landscape.
CEO Yoshiyuki Aikawa highlighted the company's commitment to growth, emphasizing plans to expand domestically and internationally. The global cosmetic surgery market, valued at $156.39 billion in 2024, is projected to grow at a 14.7% compound annual growth rate through 2030, presenting significant opportunities.
SBC Medical is pursuing multiple strategies to maintain its competitive edge, including making aesthetic medicine more accessible, offering advanced treatments, and strategically adjusting pricing. The company is particularly focusing on emerging market segments like male aesthetic procedures, where customer growth is outpacing traditional revenue streams.
Looking forward, SBC Medical plans to explore adjacent medical fields such as orthopedics, ophthalmology, and fertility treatments. With $125 million in cash reserves, the company is also considering potential acquisitions to support its expansion strategy. Wall Street analysts forecast 10% year-over-year revenue growth, projecting the company will operate 300 clinics by 2026.
